The cinobufotalin role in the treatment of liver cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12003167

Enrollment

Unknown

Registered

2012-12-19

Start date

2012-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic carcinoma

Interventions

Preventive TACE program group:Amin adriamycin, fluorouracil, mitomycin, and iodized oil

cinobufotalin group:Cinobufotalin

Eligibility

Sex/Gender

All

Age

17 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Limited to gender, aged 18-70 years old; 2. undergo radical surgery, intraoperative single tumor diameter <5cm, or the same in the two half liver tumor diameter of <5cm; 3. radical 3 months after surgery; 4. ECOG score <3 points; 5. Voluntarily participate in clinical trials, has signed an informed consent.

Exclusion criteria

Exclusion criteria: 1. Child graded C-level; 2. Intrahepatic recurrence and metastasis or liver metastasis; 3. Preoperative TACE surgery or other cancer treatment; patients receiving anti-cancer therapy; 4. active hepatitis are receiving antiretroviral treatment; 5. associated with renal insufficiency: Cr> 133umol/L; 6. Associated with other programs that may affect the regimen.

Design outcomes

Primary

Measure	Time frame
Laboratory tests;General condition score (ECOC ratings);Imaging studie;	—

Countries

China

Contacts

Public ContactXu Jing

jxuapr@yahoo.com.cn+86 13877160601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026